Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

Wednesday, January 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Raul Rodriguez will provide a company overview during the event. The conference is a significant platform for showcasing Rigel's advancements in therapies for hematologic disorders and cancer.
Price reaction · baseline $43.28 (2026-01-06 close) · hit pre-market · 2 other RIGL headline(s) in the window, move may be shared
day 0 close · peak
+8.7%
day 1
+2.8%
day 3
-7.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel Pharmaceuticals is actively participating in a major healthcare conference.
  • The presentation may enhance visibility and interest in Rigel's therapies.
  • The company is focused on improving treatments for hematologic disorders and cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.,Jan. 7, 2026/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 3:00 p.m. PT (6:00 p.m. ET).
To access the live webcast or archived recording, visit the Investor Relations section of the company's website atwww.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About RigelRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.

Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232[email protected]

Media:David RosenArgot Partners646.461.6387[email protected]

Frequently Asked Questions

When will Rigel present at the J.P. Morgan Conference?

Rigel will present on January 14, 2026, at 3:00 p.m. PT.

Who will present for Rigel Pharmaceuticals?

Raul Rodriguez, the president and CEO, will present the company overview.

Where can I access the presentation?

The live webcast and archived recording will be available on Rigel's website.

What is Rigel Pharmaceuticals focused on?

Rigel focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals J.P. Morgan Healthcare Conference Raul Rodriguez hematologic disorders cancer
Last updated: Jan 7, 2026

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →